This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chong, G. Articles by Scott, A. M. Search for Related Content PubMed PubMed Citation Articles by Chong, G. Articles by Scott, A. M.

Phase I Trial of ¹³¹I-huA33 in Patients with Advanced Colorectal Carcinoma

Authors' Affiliations: ¹ Ludwig Institute for Cancer Research, ² Departments of Nuclear Medicine and Centre for Positron Emission Tomography, Austin Hospital, Melbourne, Australia and ³ Ludwig Institute for Cancer Research, New York, New York

Requests for reprints: Andrew M. Scott, Tumour Targeting Program, Ludwig Institute for Cancer Research, Level 1, Harold Stokes Building, Austin Hospital, 143-165 Studley Road, Heidelberg, Victoria 3084, Australia. Phone: 61-39496-5876; Fax: 61-39496-5892; E-mail: andrew.scott{at}ludwig.edu.au.

Purpose: Humanized monoclonal antibody A33 (huA33) targets the A33 antigen which is expressed on 95% of colorectal cancers. A previous study has shown excellent tumor-targeting of iodine-131 labeled huA33 (¹³¹I-huA33). Therefore, we did a phase I dose escalation trial of ¹³¹I-huA33 radioimmunotherapy.

Experimental Designs: Fifteen patients with pretreated metastatic colorectal carcinoma each received two i.v. doses of ¹³¹I-huA33. The first was an outpatient trace-labeled "scout" dose for biodistribution assessment, followed by a second "therapy" dose. Three patients were treated at 20, 30, and 40 mCi/m² dose levels, and six patients at 50 mCi/m² to define the maximum tolerated dose.

Results: Hematologic toxicity was ¹³¹I dose-dependent, with one episode of grade 4 neutropenia and two episodes of grade 3 thrombocytopenia observed at 50 mCi/m². The maximum tolerated dose was determined to be 40 mCi/m². There were no acute infusion-related adverse events, and gastrointestinal toxicity was not observed despite uptake of ¹³¹I-huA33 in bowel. Seven patients developed pruritus or rash, which was not related to ¹³¹I dose. There was excellent tumor-targeting of ¹³¹I-huA33 shown in all patients. The serum T1/2ß of ¹³¹I-huA33 was (mean ± SD) 135.2 ± 46.9 hours. The mean absorbed tumor dose was 6.49 ± 2.47 Gy/GBq. Four patients developed human anti-human antibodies. At restaging, 4 patients had stable disease, whereas 11 patients had progressive disease.

Conclusion: Radioimmunotherapy using ¹³¹I-huA33 shows promise in targeting colorectal tumors, and is deliverable at a maximum tolerated dose of 40 mCi/m². Further studies of ¹³¹I-huA33 in combination with chemotherapy are planned.

This article has been cited by other articles:

				S. Shibata, A. Raubitschek, L. Leong, M. Koczywas, L. Williams, J. Zhan, and J. Y.C. Wong A Phase I Study of a Combination of Yttrium-90-Labeled Anti-Carcinoembryonic Antigen (CEA) Antibody and Gemcitabine in Patients with CEA-Producing Advanced Malignancies Clin. Cancer Res., April 15, 2009; 15(8): 2935 - 2941. [Abstract] [Full Text] [PDF]

				M. M. Bertagnolli Radioimmunotherapy for Colorectal Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4637 - 4638. [Full Text] [PDF]